183 related articles for article (PubMed ID: 36872385)
21. The effectiveness of EVOSKINĀ®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng Z; Yan P; Hou X; Feng J; He X; Yang K
Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
[TBL] [Abstract][Full Text] [Related]
23. Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy.
Hsu YH; Shen WC; Wang CH; Lin YF; Chen SC
Eur J Oncol Nurs; 2019 Dec; 43():101670. PubMed ID: 31586645
[TBL] [Abstract][Full Text] [Related]
24. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr DJ; Houlston RS; Escott-Price V; Cheadle JP
Int J Cancer; 2022 Sep; 151(6):957-966. PubMed ID: 35467766
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors of Capecitabine-Induced Hand-Foot Syndrome: A Single-Institution, Retrospective Study.
Kanbayashi Y; Taguchi T; Ishikawa T; Otsuji E; Takayama K
Oncology; 2023; 101(7):407-414. PubMed ID: 37075722
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Kao YS; Lo CH; Tu YK; Hung CH
Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
[TBL] [Abstract][Full Text] [Related]
27. Hand-foot syndrome induced by chemotherapy drug: Case series study and literature review.
Zaiem A; Hammamia SB; Aouinti I; Charfi O; Ladhari W; Kastalli S; Aidli SE; Lakhoua G
Indian J Pharmacol; 2022; 54(3):208-215. PubMed ID: 35848692
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.
Dong SQ; Wang TM; Zhang JB; He YQ; Xue WQ; Wu ZY; Yang DW; Cao LJ; Huang JW; Li XZ; Zhang PF; Zheng XH; Jia WH
Cancer Res Treat; 2021 Jul; 53(3):724-732. PubMed ID: 33285053
[TBL] [Abstract][Full Text] [Related]
29. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.
Lin S; Yue J; Guan X; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Cancer Commun (Lond); 2019 Oct; 39(1):57. PubMed ID: 31601265
[TBL] [Abstract][Full Text] [Related]
32. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
[TBL] [Abstract][Full Text] [Related]
33. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.
Liao X; Huang L; Yu Q; He S; Li Q; Huang C; Yuan X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):785-792. PubMed ID: 32193619
[TBL] [Abstract][Full Text] [Related]
34. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Zhang RX; Wu XJ; Lu SX; Pan ZZ; Wan DS; Chen G
J Cancer Res Clin Oncol; 2011 Jun; 137(6):953-7. PubMed ID: 21113620
[TBL] [Abstract][Full Text] [Related]
35. Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database.
Yoshida Y; Sasaoka S; Tanaka M; Matsumoto K; Inoue M; Satake R; Shimada K; Mukai R; Suzuki T; Iwata M; Goto F; Mori T; Mori K; Yoshimura T; Nakamura M
Ther Adv Drug Saf; 2022; 13():20420986221101963. PubMed ID: 35646307
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis - systematic review and Bayesian network meta-analysis.
Ramasubbu MK; Maji S; Padhan M; Maiti R; Hota D; Majumdar SKD; Srinivasan A
BMJ Support Palliat Care; 2022 Dec; ():. PubMed ID: 36564149
[TBL] [Abstract][Full Text] [Related]
37. [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
Takeda K; Shigematsu T; Shirai M; Yamagiwa K; Amamori K; Sunda K; Yamanda T
Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():74-6. PubMed ID: 23268906
[TBL] [Abstract][Full Text] [Related]
38. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
39. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
40. A meta-analysis of efficacy and safety of S-1 monotherapy or combination therapy as first-line treatment in metastatic colorectal cancer.
Wang Z; Wang MM; Zhou WL; Ye CY; Dai WP; Liu XL; Zhang GM; Cheng GL; Zang YS
Int J Colorectal Dis; 2020 Aug; 35(8):1567-1574. PubMed ID: 32394076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
